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Impact of Results of a Rapid Staphylococcus aureus Diagnostic Test on
Prescribing of Antibiotics for Patients with Clustered Gram-Positive
Cocci in Blood Cultures
Jane Davies,a,b* Claire L. Gordon,a,b* Steven Y. C. Tong,a,c Robert W. Baird,b and Joshua S. Davisa,c
Department of Infectious Diseases, Royal Darwin Hospital, Darwin, Australiaa; Department of Microbiology, Royal Darwin Hospital, Darwin, Australiab; and Menzies School
of Health Research and Charles Darwin University, Darwin, Australiac
In tropical northern Australia, approximately 20% of Staphylococcus aureus bacteremia is caused by methicillin-resistant
Staphylococcus aureus (MRSA). We prospectively evaluated the impact on clinician antibiotic prescribing of the results obtained
from performing the GeneXpert MRSA/SA test on 151 positive blood cultures with clustered Gram-positive cocci. The
GeneXpert result led to earlier appropriate prescription of vancomycin for 54% of patients withMRSA; 25% of patients avoided
vancomycin, and 16% of patients had all antibiotics ceased.
Community-acquired methicillin-resistant Staphylococcus au-reus (MRSA) is becoming increasingly prevalent in many
parts of the world (3), including northern Australia (11). When a
positive blood culture (BC) revealsGram-positive cocci in clusters
(GPCC), the choice of initial antibiotics is a balance between
breadth of coverage for the likely pathogen and avoidance of un-
necessary antibiotic use. From the time a blood culture signals
positive, oxacillin susceptibility testing for S. aureus can take as
long as 48 h using standard laboratory methods or as little as 90
min for targeted molecular methods (4, 5, 7, 8, 10, 12). There are
few prospective studies investigating whether the earlier knowl-
edge of a MRSA, methicillin-susceptible S. aureus (MSSA), or co-
agulase-negative staphylococcus (CNS) isolate influences antibi-
otic prescribing (9).
We prospectively evaluated the impact on clinician antibiotic
prescribing of using the second-generation GeneXpert Xpert
MRSA/SABC test (hereinafter “the GeneXpert”; Cepheid, Sunny-
vale, CA) on all positive BCs (BacT/Alert system; bioMérieux,
Durham, NC) containing GPCCs between December 2010 and
July 2011. In addition, we investigated laboratory factors that may
predict an S. aureus bacteremia rather than a CNS bacteremia.
Inclusion criteria included an age of 18 years or above, time from
collection to positivity of less than 48 h, and no previous positive
BCs with GPCCs in the past 30 days.
BCs with GPCCs were tested using the second-generation
GeneXpert according to themanufacturer’s instructions. The sec-
ond-generation GeneXpert was validated against the first-gener-
ation GeneXpert using 24 BCs with GPCCs (100% concordance),
and thereafter, only the second-generation GeneXpert was used.
In addition, BCs with GPCCs were also processed according to
standard laboratory procedures, including the use of the Vitek 2
(bioMérieux, Durham, NC) for identification and antibiotic sus-
ceptibility testing (11). MRSA isolates were defined as nonmulti-
resistant or multiresistant as described previously (11).
After GPCCs were detected in BC fluid, the treating physician
was contacted throughout the working day (0800 to 1600) by tele-
phone and informed of this. For those BCs which flagged out of
hours, the clinician was contacted at 0800 the next day. Using a
structured questionnaire, the clinician was asked for current an-
tibiotic therapy and what antibiotics they would prescribe based
on the Gram stain result. They were then informed of the Gene-
Xpert result and asked what antibiotics they would now prescribe.
Antibiotics considered appropriate forMRSA included vancomy-
cin or teicoplanin and forMSSA included cefazolin, flucloxacillin,
piperacillin-tazobactam, ticarcillin-clavulanic acid, meropenem,
teicoplanin, and vancomycin.
Approval was obtained from the Human Research Ethics
Committee of the Northern Territory Department of Health and
Menzies School of Health Research (approval HREC-2010-1436).
Proportions were compared using Fisher’s exact test and contin-
uousmeasures using Student’s t test or rank-sum test for normally
distributed and nonparametric data, respectively, using STATA,
version 11.0 (StataCorp, College Station, TX). A P value of0.05
was considered significant.
One hundred fifty-one patients had a BC with GPCCs (Table
1), of which 33 (22%) were confirmed to be S. aureus. Several
genetic variants of S. aureus occur in our region (including the
phylogenetically divergent clonal complex 75) (11); however, the
GeneXpert was able to detect all S. aureus isolates. Four CNSs gave
an invalid result on the GeneXpert, which was due to the operator
error of adding too much BC fluid. Compared with the pheno-
typic result, the sensitivity and specificity of the second-genera-
tion GeneXpert for differentiating S. aureus from non-S. aureus
isolates were 100% and 96.7%, respectively (when invalid results
were considered to be false positives), similar to previous reports
for the first-generation product (5, 7, 12).
Before the BC became positive, only 30% of patients with S.
aureus bacteremia were receiving appropriate antibiotics (Table
2). Following notification of only the Gram stain result to the
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clinician, nearly all patients with MSSA bacteremia would have
been prescribed an appropriate antibiotic, while only 46% of pa-
tients who cultured MRSA would have been. Following notifica-
tion of the GeneXpert result, all patients with MRSA were appro-
priately prescribed vancomycin. A GeneXpert result of either
MSSA or CNS resulted in 36 patients appropriately avoiding van-
comycin after the BC became positive. Compared to the antibiot-
ics the clinician would have prescribed following the Gram stain
result, 64/151 patients (42%) had a different antibiotic regimen
prescribed following the knowledge of the GeneXpert result, in-
cluding 24/151 patients (16%) with CNS who had antibiotics
stopped completely.
In comparison to patients with CNS isolated, patients with S.
aureus bacteremia were more likely to be male (odds ratio [OR],
2.12; 95% confidence interval [95%CI], 1.0 to 4.7), have a history
of fever at the time the BCwas taken (OR, 2.8; 95%CI, 1.0 to 7.4),
and have both BC bottles positive (OR. 5.9; 95% CI. 2.4 to 14.7).
BC bottles culturing S. aureus signaled positive earlier than BCs
culturing CNS, with 92% (22/24) of S. aureus BCs signaling posi-
tivewithin 24 h comparedwith 60%(52/86) ofCNS (OR, 7.2; 95%
CI, 1.5 to 34.9) (Table 1).
The proportion of S. aureus bacteremia due to MRSA was
higher in our study (31%) than in earlier reports but is consistent
with the gradual increase in local MRSA bacteremia previously
reported (11). We found the second-generation GeneXpert accu-
rate and easy to use (sensitivity, 100%; specificity, 96.7%). There
were no false-positive results due to mixed MSSA (empty cassette
variant) or methicillin-resistant CNS documented, although this
is a recognized limitation of this assay (12). Compared with the
Gram stain result, knowledge of the GeneXpert result increased
the proportion of MRSA bacteremia patients appropriately re-
ceiving vancomycin from46%to100%, confirming that theGene-
Xpert resulted in more accurate and timely antibiotic prescribing
for those patients with MRSA bacteremia.
Another option with rising MRSA rates would be to empiri-
cally commence vancomycin in all patients with GPCC in a BC.
Economic analysis has shown that rapid PCR testing for MRSA
has the potential to reduce mortality rates and be substantially
cheaper than empirical vancomycin across the United States and
Europe at a wide range of different MRSA prevalence rates (2).
Our data appear consistent with this; knowing the GeneXpert re-
sult led to 27% (41/151) of our study population avoiding vanco-
mycin completely. Just over a third of patients changed antibiotics
following the notification of the GeneXpert result (50 patients
with CNS, 5 patients with MRSA, and 10 patients with MSSA),
including 16% in whom antibiotics were stopped completely. The
use of the GeneXpert in our center is likely to have been cost
effective, although a formal cost analysis was not an original aimof
our study: assuming that the time taken forGPCCs to be identified
as S. aureus or CNS is 24 h, the cost of a GeneXpert kit is $85, the
cost of a bed day is $1,168 (6), and the cost of vancomycin is $30
per day, the use of the GeneXpert in our 151 patients led to net
TABLE 1 Clinical and laboratory characteristics of patients with
clustered Gram-positive cocci isolated from blood culturesa
Patient characteristic
Patients with clustered Gram-
positive cocci isolated from BCs
(n 151)
P value
Coagulase-negative
Staphylococcus
isolates (n 118)
S. aureus
isolates
(n 33)
Male [no. (%)] 46 (39) 19 (58) 0.044
Yr of age [median (IQR)] 53 (43–69) 56 (44–60) 0.97
Reason BC takenb
Fever [no. (%)] 70 (60) 26 (81) 0.021
Suspected infection without
fever [no. (%)]
46 (40) 6 (19) 0.021
BC taken2 days after
admission [no. (%)]
14 (12) 7 (21)c 0.14
Laboratory characteristics
Time (h) to BC positivity
[median (IQR)]d
22 (20–26) 15 (14–19) 0.001
Time-to-positivity less than
24 h [no. (%)]d
52 (60) 22 (92) 0.002
Two of 2 BC bottles positive
[no. (%)]
33 (28) 23 (70) 0.001
C-reactive protein [median
(IQR)]
51 (18–121) 91 (37–152) 0.09
White cell count109/liter
[median (IQR)]
11 (8–15) 13 (8–17) 0.30
Neutrophil count109/liter
[median (IQR)]
8 (5–12) 11 (7–14) 0.18
a MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; BC, blood culture; IQR, interquartile range.
b The number of patients in the non-S. aureus group was 116, and the number in the S.
aureus group was 32.
c Includes 2 patients with MSSA and 5 patients with MRSA.
d Time-to-positivity data were available for 110 patients.
TABLE 2 Clinician antibiotic prescribing before and after the results of
GeneXperta
Antibiotic prescribingb
Non-S. aureus
isolates
(n 118)
S. aureus isolates
(n 33)
P value
MRSA
(n 11)c
MSSA
(n 22)
On appropriate antibiotics
when BC flagged
positive
1 9 0.066
Clinician decided on
appropriate antibiotics
after the result of BC
Gram stain
5d 21d 0.002
On appropriate antibiotics
after result of Xpert
MRSA/SA BC
10d 21d 0.56
Compared to the chosen
antibiotic after the
Gram stain, clinician
antibiotic choice
changed following
Xpert MRSA/SA BC
result
50 5 10
a MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible
Staphylococcus aureus; BC, blood culture.
b Antibiotics considered appropriate for MRSA included vancomycin and for MSSA
included cephazolin, flucloxacillin, pipercillin-tazobactam, ticlarcillin-clavulanic acid,
meropenem, teicoplanin, and vancomycin.
c There were 9 nonmultiresistant MRSA isolates and 2 multiresistant MRSA isolates.
One BC cultured both multiresistant MRSA and MSSA and was included in the MRSA
group.
d Two patients with S. aureus bacteremia had antibiotic treatment withdrawn for
reasons of palliative care (one with MRSA and one with MSSA).
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savings of $16,637 over a 7-month period. Our cost analysis is
limited in being an inferred estimate of reductions in antibiotic
use, hospital stay, and drug administration. Therefore, it probably
underestimates the true cost effectiveness of using a rapid PCR
test. For example, Bauer et al. also demonstrated that the intro-
duction of a rapid PCR MRSA/SA BC test resulted in timely and
effective therapy and that it decreased length of stay and hospital
costs (1).
A further limitation of this study is the time lag in liaising with
treating clinicians regarding results that flagged positive outside
standardworking hours. The impact on antibiotic prescribing and
cost savings may therefore be greater than we have reported if the
assay were performed 24 h a day. However, our results reflect the
real-world setting of a laboratorywhere it is not feasible to provide
such a rapid diagnostic modality outside working hours.
Early identification of S. aureus isolates, including MRSA, us-
ing the GeneXpert reduces unnecessary prescription of antibiotics
and increases the likelihood that patients with MRSA will receive
early appropriate vancomycin therapy.
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